Available from stock

Trilostane

SKU: T0449

Category: Steroids

Synonyms: Desopan , Modrefen , Vetoryl , WIN 24,540 , (4α,5α,17β)-3,17-dihydroxy-4 , 5-epoxyandrost-2-ene-2-carbonitrile; 13647-35-3
CAS-Number: C₂₀H₂₇NO₃
Molecular Formula: 329.43
Molecular Weight

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Appearance: White to off-white powder
Identity: 1H-NMR

Properties

Solvents: DMSO (15 mg/ml), DMF (20 mg/ml)

Shipping: AMBIENT
Short Term Storage: RT
Long Term Storage: +4°C
Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at +4°C.

Hazard statements: H315-H319-H361
Precautionary statements: P281-P305 + P351 + P338
GHS Symbol: GHS07+GHS08
Transportation: Not dangerous goods

Description: Trilostane is an inhibitor of the 3β-HSDs (3β-HSD1 and 3β-HSD2 with Ki values of 0.10 and 1.60 ?M, respectively) which plays a role in adrenal steroid biosynthesis. 3β-hydroxysteroid dehydrogenase (3β-HSD) type 1 and type 2 isoforms are key enzymes for the biosynthesis of all active steroid hormones. 3β-HSD1 (type I) is expressed in placenta and peripheral tissues including breast tumors, whereas 3β-HSD2 (type 2) is expressed in the adrenal gland, ovary and testis. While Trilsotane has been approved for use in the treatment of Cushing’s syndrome in dogs to reduce cortisol, aldosterone and corticosterone levels, it is being investigated as a possible treatment for both breast cancer and prostate cancer to prevent the synthesis of estrogens and androgens from endogenous precursors. Trilostane has also anti-inflammatory and analgesic properties and systemic administration of trilostane directly affected peripheral and brain levels in neuroactive steroids and monoamine turnover, resulting in antidepressant activity.
Smiles: OC1=C(C#N)C[C@@]2(C)[C@@]3(CC[C@]4([H])[C@]2([H])CC[C@@]5(C)[C@@]4([H])CC[C@@H]5O)[C@@H]1O3
InChi Key: KVJXBPDAXMEYOA-CXANFOAXSA-N
References: (1) J.R. Puddefoot, et al., Expert Opin. Pharmacother. 7, 2413 (2006) (Review) , (2) J.L. Thomas, et al., J. Ster. Biochem. Mol. Biol. 111, 66 (2008) , (3) T. Machida, et al., J. Vet. Med. Sci. 70, 317 (2008) , (4) J. Espallergues, et al., Psychoneuroendocrinol. 34, 644 (2009) , (5) I. Takizawa, et al., Cancer Lett. 297, 226 (2010) , (6) J.L. Thomas, et al., J. Ster. Biochem. Mol. Biol. 125, 57 (2011) , (7) Y. Obata, et al., Intern. Med. 50, 2621 (2011) , (8) J. Espallergues, et al., Neuropharmacol. 62, 492 (2012) , (9) D. Tung, et al., Curr. Ther. Res. Clin. Exp. 75, 71 (2013) , (10) J. Lemetayer & S. Blois, Can. Vet. J. 59, 397 (2018)
InChi: InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1

Trilostane is an inhibitor of the 3β-HSDs (3β-HSD1 and 3β-HSD2 with Ki values of 0.10 and 1.60 ?M, respectively) which plays a role in adrenal steroid biosynthesis. 3β-hydroxysteroid dehydrogenase (3β-HSD) type 1 and type 2 isoforms are key enzymes for the biosynthesis of all active steroid hormones. 3β-HSD1 (type I) is expressed in placenta and peripheral tissues including breast tumors, whereas 3β-HSD2 (type 2) is expressed in the adrenal gland, ovary and testis. While Trilsotane has been approved for use in the treatment of Cushing’s syndrome in dogs to reduce cortisol, aldosterone and corticosterone levels, it is being investigated as a possible treatment for both breast cancer and prostate cancer to prevent the synthesis of estrogens and androgens from endogenous precursors. Trilostane has also anti-inflammatory and analgesic properties and systemic administration of trilostane directly affected peripheral and brain levels in neuroactive steroids and monoamine turnover, resulting in antidepressant activity.

SKU: T0449 Category: Steroids

Additional information

Additional information

Synonyms	Desopan, Modrefen, Vetoryl, WIN 24,540, (4α,5α,17β)-3,17-dihydroxy-4, 5-epoxyandrost-2-ene-2-carbonitrile
Purity	≥98% (HPLC)
Appearance	White to off-white powder
CAS-Number	13647-35-3
Molecular Formula	C20H27NO3
Molecular Weight	329.43
Identity	1H-NMR
Solvents	DMSO (15 mg/ml), DMF (20 mg/ml)
Smiles	OC1=C(C#N)C[C@@]2(C)[C@@]3(CC[C@]4([H])[C@]2([H])CC[C@@]5(C)[C@@]4([H])CC[C@@H]5O)[C@@H]1O3
InChi Key	KVJXBPDAXMEYOA-CXANFOAXSA-N
Shipping	AMBIENT
Short Term Storage	RT
Long Term Storage	+4°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at +4°C.
Hazard statements	H315-H319-H361
Precautionary statements	P281-P305 + P351 + P338
GHS Symbol	GHS07+GHS08
Transportation	Not dangerous goods
References	(1) J.R. Puddefoot, et al., Expert Opin. Pharmacother. 7, 2413 (2006) (Review), (2) J.L. Thomas, et al., J. Ster. Biochem. Mol. Biol. 111, 66 (2008), (3) T. Machida, et al., J. Vet. Med. Sci. 70, 317 (2008), (4) J. Espallergues, et al., Psychoneuroendocrinol. 34, 644 (2009), (5) I. Takizawa, et al., Cancer Lett. 297, 226 (2010), (6) J.L. Thomas, et al., J. Ster. Biochem. Mol. Biol. 125, 57 (2011), (7) Y. Obata, et al., Intern. Med. 50, 2621 (2011), (8) J. Espallergues, et al., Neuropharmacol. 62, 492 (2012), (9) D. Tung, et al., Curr. Ther. Res. Clin. Exp. 75, 71 (2013), (10) J. Lemetayer & S. Blois, Can. Vet. J. 59, 397 (2018)
InChi	InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1
Quantity	10 mg, 50 mg, Bulk